Bisphosphonate-related jaw necrosis: A team approach management and prevention

Authors

  • S Rayman,

    1. Authors’ affiliations:
      Salim Rayman, Dental Hygiene, Eugenio Maria de Hostos Community College, The City University of New York, New York, NY, USA
      Khalid Almas, Division of Periodontology, University of Connecticut School of Dental Medicine, Farmington, CT, USA
      Elvir Dincer, Dental Hygiene, Eugenio Maria de Hostos Community College, The City University of New York, New York, NY, USA
    Search for more papers by this author
  • K Almas,

    1. Authors’ affiliations:
      Salim Rayman, Dental Hygiene, Eugenio Maria de Hostos Community College, The City University of New York, New York, NY, USA
      Khalid Almas, Division of Periodontology, University of Connecticut School of Dental Medicine, Farmington, CT, USA
      Elvir Dincer, Dental Hygiene, Eugenio Maria de Hostos Community College, The City University of New York, New York, NY, USA
    Search for more papers by this author
  • E Dincer

    1. Authors’ affiliations:
      Salim Rayman, Dental Hygiene, Eugenio Maria de Hostos Community College, The City University of New York, New York, NY, USA
      Khalid Almas, Division of Periodontology, University of Connecticut School of Dental Medicine, Farmington, CT, USA
      Elvir Dincer, Dental Hygiene, Eugenio Maria de Hostos Community College, The City University of New York, New York, NY, USA
    Search for more papers by this author

Dr Khalid Almas
Division of Periodontology
University of Connecticut School of Dental Medicine
Farmington
CT, USA
Tel.: +1 860 679 3721
Fax: +1 860 679 1027
E-mail: khalidalmas@yahoo.com

Abstract

Abstract:  Osteonecrosis means the process of bone death. Bisphosphonates (BPs) are becoming recognized increasingly as having a significant impact on dental treatments. BPs are the most widely used class of anti-resorptive drugs. They prevent bone resorption through osteoclast inhibition and are considered the standard of care for the management of metastatic bone disease. BPs are used for the treatment of skeletal disorders such as osteoporosis, hypercalcaemia of malignancy, ostoelytic lesions arising from solid tumours and Paget’s disease, breast cancer or prostate cancer. Jaw necrosis appears to be associated with the intravenous (i.v.) use of BPs. The aim of this review paper is to update the understanding of healthcare professionals to the osteonecrosis of jaws, mechanism of action and classification of BPs, management of the patients with BP-related osteonecrosis (BRON) of the jaws. An interdisciplinary approach has been emphasized to prevent and manage the condition. Finally, the role of dental practitioners including dental hygienists has been discussed to early diagnose the BRON and improve the quality of life of patients with the condition.

Ancillary